Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
M J BurkeCarrie Kitko

Abstract

Survival for children with relapsed T cell acute lymphoblastic leukemia (T-ALL) is poor when treated with chemotherapy alone, and outcomes after allogeneic hematopoietic cell transplantation (HCT) is not well described. Two hundred twenty-nine children with T-ALL in second complete remission (CR2) received an HCT after myeloablative conditioning between 2000 and 2011 and were reported to the Center for International Blood and Marrow Transplant Research. Median age was 10 years (range, 2 to 18). Donor source was umbilical cord blood (26%), matched sibling bone marrow (38%), or unrelated bone marrow/peripheral blood (36%). Acute (grades II to IV) and chronic graft-versus-host disease occurred in, respectively, 35% (95% confidence interval [CI], 27% to 45%) and 26% (95% CI, 20% to 33%) of patients. Transplant-related mortality at day 100 and 3-year relapse rates were 13% (95% CI, 9% to 18%) and 30% (95% CI, 24% to 37%), respectively. Three-year overall survival and disease-free survival rates were 48% (95% CI, 41% to 55%) and 46% (95% CI, 39% to 52%), respectively. In multivariate analysis, patients with bone marrow relapse, with or without concurrent extramedullary relapse before HCT, were most likely to relapse (hazard ratio, 3....Continue Reading

References

Nov 30, 1999·Hematology/oncology Clinics of North America·M E FlowersK M Sullivan
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagen Graf EinsiedelGünter Henze
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra H FilipovichMary E D Flowers
Oct 21, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard H KoMignon L Loh
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gesche TallenArend von Stackelberg
Jan 3, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Denise M OlianskyUNKNOWN American Society for Blood and Marrow Transplantation
Mar 14, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen P HungerWilliam L Carroll
Mar 31, 2012·Medicina clínica·Susana RivesUNKNOWN grupo cooperativo SHOP (Sociedad Española de Hemato-Oncología Pediátrica)
Jul 25, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mohammad BakrMahmoud Aljurf
May 9, 2013·Journal of Pediatric Hematology/oncology·Bettina ReismüllerUNKNOWN Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group

❮ Previous
Next ❯

Citations

Jul 28, 2016·Nature Reviews. Cancer·Laura Belver, Adolfo Ferrando
Feb 28, 2020·Expert Review of Clinical Immunology·Caroline Diorio, David T Teachey
Oct 2, 2019·Cold Spring Harbor Perspectives in Medicine·Francesca GianniAdolfo Ferrando
Dec 18, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christina PetersPeter Bader
May 20, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Cornelia EckertVaskar Saha

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Erica WarlickMark R Litzow
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Michael R VernerisS M Davies
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Li Mei PoonP Kebriaei
© 2021 Meta ULC. All rights reserved